Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Many of the pediatric malignancies are not curable on progression on front line or 2nd line
chemotherapy. Further therapy with conventional drugs imposes many side effects and decreases
the QOL. The usual therapy offered to such patients is best supportive care.
Metronomic chemotherapy can induce tumor stabilization or tumor responses in patients with
cancer that are refractory or have relapsed after conventional chemotherapy. Whether
metronomic therapy is better than best supportive care is not known. In order to do so, a
study is required which may compare metronomic therapy with a placebo therapy on PFS and QOL
in relapsed refractory cases of pediatric solid tumors who have failed at least two lines of
chemotherapy.
HYPOTHESIS
The investigators hypothesize that metronomic chemotherapy in progressive pediatric
malignancy will improve PFS and QOL. If validated, then this form for therapy will be an
option for both the patients and the clinicians, who are left with just an option of best
supportive care in such situations of progressive pediatric cancers despite multiple lines of
chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi